BioPharmX Corporation reported its Q1 2020 financial results, reporting an overall better performance than the last year. However, the results cannot be considered good yet. The pharmaceutical company reported smaller net losses and less operating expenses compared to the previous year. BioPharmX’s total operating expenses for the reported quarter were $3.6m. This figure can be compared with total operating expenses of $4.4m, which were reported in the previous year’s quarter.
Net losses were reported to be $3.6 million, and the figure is an improvement to the previous year’s result of $4.4 million. Looking at it from a per-share perspective, this year’s net loss per share is $0.38. On the other hand, the previous year’s result was $0.61 per share. Non-GAAP net losses got reported to be $0.36 per share versus $0.52 per share from the previous year’s quarter.